Capmatinib’s launch time and indications
Introduction: Capmatinib is a small molecule hepatocyte growth factor receptor inhibitor that was approved by the U.S. Food and Drug Administration on May 6, 2020 for the treatment of adult patients with metastatic non-small cell lung cancer with mesenchymal-epithelial transition exon 14 skipping mutations. Clinical trials have shown that capmatinib has good clinical efficacy. Common adverse reactions include increased serum creatinine, nausea and vomiting, etc., and is well tolerated by patients.
Capmatinib’s launch in China
Capmatinib has been launched in some regions in China, such as Taiwan, China, and Hong Kong, China. The launch times are June 17, 2021, and February 26, 2021, respectively. However, as of April 12, 2024, capmatinib has not yet been launched in mainland China, and the specific launch time is unclear.
Indications
is a kinase inhibitor that targets the c-Met receptor tyrosine kinase and is indicated for the treatment of certain types of non-small cell lung cancer (NSCLC) that have spread to other parts of the body. The specific indication is MET exon 14 skipped NSCLC. Capmatinib works by blocking the action of abnormal proteins that signal cancer cells to multiply, helping to slow or stop the spread of cancer cells.
Price information
Since capmatinib is not currently available in mainland China, the domestic price of capmatinib is not yet clear. It is understood that a box of 200 mg x 60 tablets of capmatinib generic drug produced by Lucius Pharmaceutical Factory in Laos is priced at around 2640$-2740$. The Bangladesh Everest version of capmatinib is priced around 3600$-3700$ per box of 200mg*56 capsules.
Purchase Channels
When purchasing capmatinib, it is recommended to choose formal purchase channels, such as qualified medical institutions, pharmacies or certified online platforms. Avoid purchasing from illegal or unknown sources to ensure drug quality, efficacy and safety. For online purchases, you should confirm whether the website has a legal drug sales license, check user reviews and company reputation. In addition, you can also choose regular overseas medical service institutions to purchase drugs.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)